Hypertrophic Cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Internal Medicine

Background:

• Hypertrophic cardiomyopathy (HCM) is a myocardial disease defined by hypertrophy, myocyte disarray, and fibrosis.
• Genetic mutations in cardiac sarcomeric proteins are the primary cause of most HCM cases.
• Patients experience diverse symptoms like chest pain, dyspnea, palpitations, and syncope across all age groups.

Purpose of the Study:

• To summarize the key characteristics of hypertrophic cardiomyopathy.
• To outline the primary complications, including sudden cardiac death, heart failure, and thromboembolism.
• To review current management strategies for symptom alleviation and prevention of sudden death.

Main Methods:

• Review of existing literature on hypertrophic cardiomyopathy.
• Analysis of clinical presentation and diagnostic criteria.
• Evaluation of therapeutic interventions for obstructive and non-obstructive HCM.

Main Results:

• Twenty-five percent of patients develop a dynamic left ventricular outflow tract gradient.
• Interventions targeting outflow tract obstruction often improve symptoms.
• Risk stratification aids in preventing sudden death with implantable cardioverter defibrillators.

Conclusions:

• Effective management of hypertrophic cardiomyopathy requires addressing symptoms and preventing sudden cardiac death.
• Treatment strategies vary based on the presence and severity of left ventricular outflow tract obstruction.
• Clinical risk stratification is crucial for guiding prophylactic therapy in high-risk individuals.